Literature DB >> 7804438

Clinical relevance of somatostatin receptor imaging.

J C Reubi1.   

Abstract

Mesh：

Substances：

Year:  1994        PMID： 7804438     DOI： 10.1530/eje.0.1310575

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN： 0804-4643            Impact factor:   6.664


× No keyword cloud information.
  4 in total

1.  Usefulness of somatostatin receptor scintigraphy in the management of patients with Zollinger-Ellison syndrome. Groupe de Recherche et d'Etude du Syndrome de Zollinger-Ellison (GRESZE).

Authors:  G Cadiot; G Bonnaud; R Lebtahi; L Sarda; P Ruszniewski; D Le Guludec; M Mignon
Journal:  Gut       Date:  1997-07       Impact factor: 23.059

Review 2.  Carcinoid tumours.

Authors:  S Janmohamed; S R Bloom
Journal:  Postgrad Med J       Date:  1997-04       Impact factor: 2.401

3.  Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0,Tyr3-octreotide versus 68Ga-DOTA0-lanreotide.

Authors:  Daniel Putzer; Alexander Kroiss; Dietmar Waitz; Michael Gabriel; Tatjana Traub-Weidinger; Christian Uprimny; Elisabeth von Guggenberg; Clemens Decristoforo; Boris Warwitz; Gerlig Widmann; Irene Johanna Virgolini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-11-14       Impact factor: 9.236

4.  ⁶⁸Ga-DOTA⁰-Tyr³-octreotide positron emission tomography in head and neck squamous cell carcinoma.

Authors:  Volker H Schartinger; József Dudás; Clemens Decristoforo; Christoph Url; Johannes Schnabl; Georg Göbel; Irene J Virgolini; Herbert Riechelmann; Michael Rasse; Dietmar Waitz; Daniel Putzer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-05-18       Impact factor: 9.236
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.